- Home
- FOA vs PLX Comparison
FOA vs PLX Comparison
Compare FOA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOA | PLX |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | United States |
| Employees | 747 | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 174.0M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | FOA | PLX |
|---|---|---|
| Price | $21.43 | $2.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $26.00 | $12.00 |
| AVG Volume (30 Days) | 68.0K | ★ 710.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | $0.58 | $36.81 |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.77 | $1.34 |
| 52 Week High | $29.58 | $3.19 |
Technical Indicators
Market Signals| Indicator | FOA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 40.84 |
| Support Level | $15.93 | $2.03 |
| Resistance Level | $23.84 | $2.42 |
| Average True Range (ATR) | 1.13 | 0.07 |
| MACD | 0.25 | 0.00 |
| Stochastic Oscillator | 63.46 | 23.64 |
Price Performance
Historical ComparisonAbout FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.